Daito Pharmaceutical Co., Ltd.
Stock Price Chart
2026/11/06 12:54 UpdatedPrice Trend
2026/11/06 12:54 UpdatedPrice & Trading Details
2026/11/06 12:54 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/11/01Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
373.4K | 0.00% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
248.2K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
217.8K | 0.00% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
197.1K | 0.00% | |
|
Dimensional ETF Trust-Dimensional International Small Cap Value ETF
|
164.5K | +8.80% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
146.7K | -5.23% |
Dividend History
Updated 2026/11/08| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥20 | -46.7% |
| 2025 | ¥38 | +15.4% |
| 2024 | ¥33 | +13.5% |
| 2023 | ¥29 | -3.1% |
| 2022 | ¥30 | - |
Financial Performance
2026/11/08 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥45,101M | ¥46,895M | ¥50,643M | ¥50,650M |
| Gross Profit | ¥10,331M | ¥9,839M | ¥8,637M | ¥9,897M |
| Operating Income | ¥5,208M | ¥3,894M | ¥2,620M | ¥3,637M |
| Pretax Income | ¥5,088M | ¥4,259M | ¥3,081M | ¥4,195M |
| Net Income | ¥3,600M | ¥3,295M | ¥1,908M | ¥3,161M |
| EPS | ¥113.71 | ¥105.00 | ¥62.74 | ¥107.49 |
| Operating Margin | 11.55% | 8.30% | 5.17% | 7.18% |
| Balance Sheet | ||||
| Total Assets | ¥70,552M | ¥77,708M | ¥78,004M | ¥73,291M |
| Total Equity | ¥50,672M | ¥52,068M | ¥52,003M | ¥52,891M |
| Total Liabilities | ¥19,880M | ¥25,640M | ¥26,001M | ¥20,400M |
| Cash | ¥3,607M | ¥2,727M | ¥2,207M | ¥954M |
| Interest-bearing Debt | ¥4,889M | ¥8,719M | ¥11,885M | ¥9,294M |
| Equity Ratio | 71.82% | 67.00% | 66.67% | 72.17% |
| D/E Ratio | 0.10 | 0.17 | 0.23 | 0.18 |
| Cash Flow | ||||
| Operating CF | ¥4,155M | ¥5,182M | ¥5,897M | ¥9,377M |
| Investing CF | -¥5,566M | -¥5,930M | -¥7,365M | -¥4,388M |
| Financing CF | ¥616M | -¥183M | ¥1,002M | -¥6,289M |
| Free CF | -¥1,401M | -¥1,094M | -¥1,198M | ¥4,160M |
| Efficiency | ||||
| ROE | 7.10% | 6.33% | 3.67% | 5.98% |
| ROA | 5.10% | 4.24% | 2.45% | 4.31% |
Latest IR Information
-
Notice Regarding Status of Treasury Stock Acquisition
Based on a board resolution, 216,600 shares of common stock were acquired. Total acquisition amount was 290,532,700 yen. Acquisition period was 2026/10/15–2026/10/31, acquisition method was market purchase. The upper limit was planned at 1,250,000 shares (4.4% of issued shares), but...
Read more -
FY2027 1Q Earnings Presentation
Consolidated net sales were 11.89 hundred million yen, down -8.6% year-over-year, and EBITDA was 1.68 hundred million yen, down -17.3% year-over-year. Orders remain firm from 2Q onward and full-year forecast is unchanged. Free cash flow doubled to 2.73 hundred million...
Read more -
Q1 Financial Summary for the Fiscal Year Ending May 2027 [Japan GAAP] (Consolidated)
For Q1 of the fiscal year ending May 2027, consolidated revenue was 11,894 million yen, down -8.6% year-over-year, operating income was 712 million yen, ordinary income was 808 million yen, and net income attributable to owners of parent was 700...
Read more -
Notice of Treasury Stock Acquisition and Cancellation
As part of the medium-term management plan capital policy, the Company will acquire treasury stock (up to 1,250,000 shares, 4.4%) and cancel those shares on May 31, 2027. Acquisition period: 2026/10/15–2027/5/21; total amount upper limit: 2,000 million yen.
Read more -
Daito Pharmaceutical Co.,Ltd. to Establish Jointly Funded Company for Succession of Kyorin Pharmaceutical's Generic Drug Business and Conclude Share Transfer Agreement
A co-creation organization will be established with at least three parties to succeed Kyorin Pharmaceutical's generic drug business. Daito Pharmaceutical Co.,Ltd. will hold 49.1%, Meiji Seika Pharma 36.0%, and DBJ 14.9%. The co-creation organization is scheduled to be established in...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,390
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Daito Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Japan and internationally. It offers active pharmaceutical ingredients (APIs) for generic drugs; develops and manufactures generic and over-the-counter drugs; and contract manufacturing services for ethical drugs. The company also engages in wholesale of pharmaceutical and veterinary medicine. It exports its products to the United States, as well as European and Asian countries. Daito Pharmaceutical Co., Ltd. was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co., Ltd. in 1992. Daito Pharmaceutical Co., Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
